Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside.
Mayo Clin Proc
; 99(2): 285-299, 2024 Feb.
Article
de En
| MEDLINE
| ID: mdl-38180396
ABSTRACT
Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene-related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene-related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Peptide relié au gène de la calcitonine
/
Migraines
Type d'étude:
Prognostic_studies
Limites:
Humans
Langue:
En
Journal:
Mayo Clin Proc
Année:
2024
Type de document:
Article
Pays de publication:
Royaume-Uni